Evidence map›Paper›PMID 39189975›Full record

ArticleOncotarget2024

Retraction: MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1.

Ling Xiao, Hui Zhou, Xiang-Ping Li, Juan Chen, Chao Fang, Chen-Xue Mao, Jia-Jia Cui, Wei Zhang, Hong-Hao Zhou, Ji-Ye Yin and 1 more

Abstract readEditorialRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ling XiaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Hui ZhouThe Affiliated Cancer Hospital, XiangYa School of Medicine, Central South University, Changsha, Hunan 410014, P.R. China.
Xiang-Ping LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Juan ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Chao FangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Chen-Xue MaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Jia-Jia CuiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Hong-Hao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Ji-Ye YinDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.
Zhao-Qian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungGenes, Tumor SuppressorLung NeoplasmsMicroRNAsYAP-Signaling ProteinsAnimalsGene Expression Regulation, NeoplasticHumansMicroRNAsMIRN138 microRNA, humanYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID39189975
PMCPMC11348940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.